# A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

> **NCT01218308** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5220 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** FluLaval® Quadrivalent
- **BIOLOGICAL:** Havrix™

## Key facts

- **NCT ID:** NCT01218308
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-09
- **Primary completion:** 2012-01-09
- **Final completion:** 2012-01-09
- **Target enrollment:** 5220 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218308, "A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*